全球钙化胚抗原 (CEA) 市场规模（按最终用户、应用、区域范围和预测）

钙胚抗原（CEA）市场规模及预测

预计 2024 年癌胚抗原 (CEA) 市场规模将达到 23.4 亿美元，到 2031 年将达到 37.7 亿美元，2024 年至 2031 年的复合年增长率为 6.10%。

钙胚抗原 (CEA) 是一种在胚胎组织中含量丰富的醣蛋白，在成人体内含量较低。 CEA 被用作肿瘤标记，其血液水平可以提示某些肿瘤的存在，尤其是结直肠癌。健康个体的 CEA 水平通常相对较低，但在存在恶性肿瘤（如肺癌、乳癌、胰腺癌和胃肠道癌）时可能会升高。 CEA 检测通常用于监测癌症治疗后的进展和復发，而不是用于初步诊断。后续观察升高的 CEA 水平（这可能表示疾病復发）在手术或化疗后尤其有益。

随着研究的进展，CEA 的作用预计将扩展到癌症监测之外。未来生物技术的进步可能会提高 CEA 检测的敏感度和特异性，从而有可能实现更早的癌症检测并将其作为治疗标靶。 CEA 数据还可以利用人工智慧和机器学习整合到更广泛的生物标记组中，从而实现更详细、更个人化的癌症诊断。这将有助于更准确的预后、个人化治疗并改善患者预后。液态切片技术的进步有望使基于 CEA 和其他标誌物的非侵入性血液诊断彻底改变癌症筛检和监测。

全球钙化胚抗原（CEA）市场动态

影响全球癌胚抗原 (CEA) 市场的关键市场动态包括：

关键市场驱动因素

大肠直肠癌发生率不断上升：大肠直肠癌发生率不断上升是CEA市场的主要驱动力，CEA被广泛用作此类癌症的肿瘤标记。根据世界卫生组织（WHO）下属国际癌症研究机构（IARC）的数据，2020年全球将新增约193万例大肠直肠癌病例，使其成为全球第三大常见癌症。如此高的发生率推动了CEA检测的需求，用于早期发现和监测大肠癌。

CEA 检测在癌症管理中的应用日益广泛：CEA 检测在癌症管理中的应用日益广泛，尤其是在监测治疗反应和检测復发方面，这正在推动市场成长。 《临床肿瘤学杂誌》发表的一项研究发现，CEA 监测在结直肠癌復发出现临床症状之前就能检测到 82% 的复发，这凸显了 CEA 检测在治疗后监测中的重要性。如此高的检测率正鼓励更多肿瘤科医师将 CEA 检测纳入其标准追踪方案。

CEA 检测的技术进步：CEA 检测技术的创新，例如开发更灵敏、特异性的检测方法，正在推动市场扩张。例如，根据美国美国癌症研究所的报告，使用液态切片技术（包括循环肿瘤 DNA (ctDNA) 分析）可以比传统方法更灵敏地检测 CEA。一项研究表明，ctDNA 分析可以检测出 II 期结肠癌患者术后的分子残留病灶，灵敏度高达 58%，特异性高达 98%，这有望提高 CEA 检测在癌症管理中的效用。

主要挑战

敏感性和特异性不足：CEA 检测通常缺乏足够的敏感性和特异性，尤其是在早期癌症中。 CEA 水平升高不仅限于恶性肿瘤，在吸烟、感染疾病和发炎性疾病等良性疾病中也可能升高。这会导致假阳性和假阴性，限制了效用。对于临床医生来说，这给解读 CEA 水平带来了挑战。由于单凭该标记无法可靠地区分癌症和非癌症疾病，因此需要额外的诊断工具和程序来确认或排除恶性肿瘤。

原发性诊断效用有限：CEA 在癌症復发和进展监测的应用远多于原发性诊断。这限制了其作为早期诊断工具的市场潜力。在癌症早期，CEA 水平可能仍处于正常范围内，因此并非筛检或识别恶性肿瘤早期发生的可靠指标。因此，其在癌症诊断中的应用通常有限，从而降低了一般人群对常规 CEA 检测的需求，这直接影响了市场成长和商业性价值。

来自先进生物标记的竞争：循环肿瘤DNA (ctDNA) 等新型、更灵敏的癌症生物标记和基因检测的兴起，对CEA的相关性构成了重大挑战。这些先进的标誌物提供了更高的准确性和更佳的早期检测能力。随着研发和技术创新不断开发出更全面的癌症生物标记组合，CEA通常被视为一种过时的辅助工具。人们对先进诊断方法的日益偏好降低了对CEA检测的依赖，威胁到其市场地位，并推动了持续改进的需求。

主要趋势

癌症发生率上升：全球癌症患者数量的不断增加，尤其是大肠癌和肺癌，是CEA市场的主要驱动力。由于CEA通常用于监测这些类型的癌症，因此发生率的上升直接转化为对CEA检测需求的增加。人口老化、吸烟等生活方式因素以及环境影响正在加剧癌症负担。因此，CEA在癌症诊断、监测和治疗后追踪的应用越来越频繁，这也增加了定期检测以发现復发和追踪治疗后续观察的需求。

早期癌症检测意识的提升：随着人们对早期癌症检测重要性的认识不断提高，越来越多的人开始接受定期筛检和监测。癌胚抗原 (CEA) 在后续护理中发挥着至关重要的作用，尤其对于癌症復发风险较高的人。推广早期癌症筛检和监测的宣传活动和医疗保健倡议，加上医疗基础设施的进步，正在推动对 CEA 等肿瘤标记检测的需求成长。这种日益增强的意识正在推动市场成长，因为越来越多的患者和医生将 CEA 检测作为综合癌症管理策略的一部分。

诊断技术的进步：诊断技术的创新，例如检测灵敏度的提升和自动化检测平台的完善，正在推动CEA市场的发展。这些进步提高了CEA检测的准确性和便利性，使其更加可靠、便利。更新、更快速、更准确的检测方法使CEA能够更有效地纳入常规癌症监测。这些技术进步使医疗保健专业人员对CEA检测的可靠性充满信心，并使患者受益于更快的结果和更早的检测，从而推动CEA检测在临床环境中得到更广泛的应用。

目录

第 1 章全球癌胚抗原 (CEA) 市场简介

• 市场概况
• 调查范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球癌胚抗原（CEA）市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球癌胚抗原（CEA）市场应用

• 概述
• 消化系统癌症
• 乳癌
• 肺癌
• 其他的

6. 全球癌胚抗原（CEA）市场（依性别）

• 概述
• 男性
• 女士

7. 全球癌胚抗原 (CEA) 市场（依最终用户）

• 概述
• 医院
• 诊断中心
• 研究和学术机构
• 家庭
• 其他的

8. 全球癌胚抗原（CEA）市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

9. 全球癌胚抗原（CEA）市场的竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章：公司简介

• Quest Diagnostics
• Abbott Diagnostics
• Roche Diagnostics
• GenWay Biotech Inc.
• Correlogic Systems, Inc.
• Creative Diagnostics
• Omega Diagnostics Group PLC
• RayBiotech Inc.
• Boster Biological Technology

第十一章 附录

• 相关调查

Carcinoembryonic Antigen (CEA) Market Size And Forecast

Carcinoembryonic Antigen (CEA) Market size was valued at USD 2.34 Billion in 2024 and is projected to reach USD 3.77 Billion by 2031, growing at a CAGR of 6.10% from 2024 to 2031.

Carcinoembryonic Antigen ((CEA)) is a glycoprotein found largely in embryonic tissues and at low levels in adults. It is employed as a tumor marker, which means that its blood levels can signal the existence of specific tumors, particularly colorectal cancer. (CEA) levels are normally relatively low in healthy persons, but they can grow in the presence of malignancies such as lung, breast, pancreatic, and gastrointestinal cancers. (CEA) testing is most typically used to monitor the course or return of cancer after therapy, rather than for initial diagnosis. It is especially beneficial in post-surgical or chemotherapy follow-ups to monitor any increase in (CEA) levels that may suggest disease recurrence.

As research improves, (CEA)'s role is predicted to grow beyond cancer monitoring. Future advances in biotechnology may improve the sensitivity and specificity of (CEA) testing, potentially enabling early cancer identification or even the use of (CEA) as a therapeutic target. (CEA) data could be integrated into broader biomarker panels via artificial intelligence and machine learning, allowing for more thorough, customized cancer diagnosis. This could result in more precise prognoses, customized treatments, and improved patient outcomes. As liquid biopsy technologies advance, non-invasive blood diagnostics based on (CEA) and other markers could transform cancer screening and monitoring

Global Carcinoembryonic Antigen (CEA) Market Dynamics

The key market dynamics that are shaping the global carcinoembryonic antigen (CEA) market include:

Key Market Drivers:

Increasing Incidence of Colorectal Cancer: The rising prevalence of colorectal cancer is a significant driver for the (CEA) market, as (CEA) is widely used as a tumor marker for this type of cancer. According to the World Health Organization's International Agency for Research on Cancer (IARC), in 2020, there were approximately 1.93 million new cases of colorectal cancer worldwide, making it the third most common cancer globally. This high incidence rate is driving the demand for (CEA) tests for early detection and monitoring of colorectal cancer.

Growing Adoption of (CEA) Tests in Cancer Management: The increasing use of (CEA) tests in cancer management, particularly for monitoring treatment response and detecting recurrence, is driving market growth. A study published in the Journal of Clinical Oncology found that (CEA) monitoring detected 82% of colorectal cancer recurrences before they were clinically apparent, highlighting its importance in post-treatment surveillance. This high detection rate is encouraging more oncologists to incorporate (CEA) testing into their standard follow-up protocols.

Technological Advancements in (CEA) Testing Methods: Innovations in (CEA) testing technologies, such as the development of more sensitive and specific assays, are driving market expansion. For instance, a report by the National Cancer Institute states that the use of liquid biopsy techniques, including circulating tumor DNA (ctDNA) analysis, can detect (CEA) with higher sensitivity than traditional methods. One study showed that ctDNA analysis could detect post-surgical molecular residual disease in stage II colon cancer patients with 58% sensitivity and 98% specificity, potentially improving the utility of (CEA) testing in cancer management.

Key Challenges:

Lack of Sensitivity and Specificity: (CEA) tests often lack sufficient sensitivity and specificity, especially in early-stage cancers. Elevated (CEA) levels are not exclusive to malignancies; benign conditions like smoking, infections, and inflammatory diseases can also cause an increase. This leads to false positives and negatives, limiting its utility in early cancer detection. For clinicians, this creates a challenge in interpreting (CEA) levels, as the marker alone cannot reliably differentiate between cancerous and non-cancerous conditions, thus requiring additional diagnostic tools and procedures to confirm or rule out malignancies.

Limited Utility in Primary Diagnosis: (CEA) is more useful for monitoring cancer recurrence or progression than for primary diagnosis. This limits its market potential as an early diagnostic tool. Since (CEA) levels may remain within normal ranges during the early stages of cancer, it is not a reliable marker for screening or identifying the initial onset of malignancy. Consequently, its application in cancer diagnosis is often restricted, reducing the demand for routine (CEA) testing in the general population, which directly impacts its market growth and commercial value.

Competition from Advanced Biomarkers: The rise of newer, more sensitive cancer biomarkers and genetic tests, such as circulating tumor DNA (ctDNA), poses a significant challenge to (CEA)'s relevance. These advanced markers provide higher precision and better early detection capabilities. As research and technological innovations continue to develop more comprehensive panels of cancer biomarkers, (CEA) is often seen as an outdated or supplementary tool. This growing preference for advanced diagnostics reduces the reliance on (CEA) testing, threatening its market position and driving the need for continuous improvement.

Key Trends:

Rising Cancer Incidence: The global increase in cancer cases, particularly colorectal and lung cancers, is a major driver for the (CEA) market. As (CEA) is commonly used to monitor these types of cancers, the rising incidence directly correlates with a higher demand for (CEA) testing. The aging population, lifestyle factors such as smoking, and environmental influences contribute to the growing cancer burden. This results in more frequent use of (CEA) as part of cancer diagnosis, monitoring, and post-treatment follow-up, thus fueling the need for regular testing to detect recurrence or track treatment efficacy.

Growing Awareness of Early Cancer Detection: As public awareness about the importance of early cancer detection rises, more individuals undergo regular screenings and monitoring. (CEA) plays a crucial role in follow-up care, especially for those at high risk of cancer recurrence. Campaigns and healthcare initiatives promoting early cancer screening and monitoring, coupled with advancements in healthcare infrastructure, lead to a higher demand for tumor marker tests like (CEA). This increased awareness drives market growth, as more patients and physicians seek out (CEA) testing as part of a comprehensive cancer management strategy.

Advancements in Diagnostic Technologies: Innovations in diagnostic technology, such as improved assay sensitivity and automated testing platforms, are boosting the (CEA) market. These advancements enhance the accuracy and ease of conducting (CEA) tests, making them more reliable and accessible. With new, faster, and more precise testing methods, (CEA) can be integrated into routine cancer monitoring more effectively. This technological progress has led to greater adoption of (CEA) testing in clinical practice, as healthcare providers become more confident in its reliability and patients benefit from faster results and earlier detection.

Global Carcinoembryonic Antigen (CEA) Market Regional Analysis

Here is a more detailed regional analysis of the global carcinoembryonic antigen (CEA) market:

North America:

North America remains a dominating participant in the Carcinoembryonic Antigen ((CEA)) testing market, because of advanced healthcare systems and rising cancer rates, notably colorectal and lung malignancies. The high prevalence of these malignancies, combined with (CEA)'s importance as a biomarker, drives demand for diagnostic testing. In 2023 alone, the United States is expected to have 153,020 new colorectal cancer cases, with lung cancer accounting for 238,340 new cancer-related fatalities. The increase in survival rates for these tumors, owing to early detection approaches such as (CEA) testing, emphasizes its importance in the region's healthcare scene.

The global (CEA) market is also expected to rise rapidly, owing to advances in biomarker testing technologies and increased acceptance of customized medicine. According to studies, combining (CEA) with additional biomarkers greatly boosts detection rates, hence increasing early diagnosis efforts. With the worldwide cancer biomarkers market predicted to increase at a 12.2% CAGR until 2028, continuous research and technological innovations will continue to fuel market growth. North America's emphasis on precision medicine and early cancer detection, combined with significant research initiatives, strengthens its position in the worldwide (CEA) market.

Asia-Pacific:

The Asia-Pacific region is witnessing rapid growth in the Carcinoembryonic Antigen ((CEA)) market, driven primarily by a rising cancer incidence, advancements in healthcare infrastructure, and increasing awareness of early cancer detection. As cancer rates climb, particularly with projections showing a 30.7% rise in new cancer cases from 8.8 million in 2018 to 11.5 million by 2030 (WHO), the demand for diagnostic tests like (CEA) is expected to surge. These factors contribute to the rising accessibility and availability of (CEA) testing across the region.

Another significant driver is the increase in disposable incomes and the expansion of the middle class, allowing more individuals to afford advanced diagnostic procedures like (CEA) testing. The Asian Development Bank forecasts the middle-class population in Asia will grow to 3.5 billion by 2030, which will significantly boost demand for healthcare services. Additionally, the growing prevalence of colorectal cancer, one of the primary cancers detected by (CEA) tests, is further fueling market growth. GLOBOCAN 2020 estimates a 60% rise in colorectal cancer cases by 2040 in Asia, reinforcing the need for more widespread diagnostic testing. Government initiatives, such as China's "Healthy China 2030" plan to improve early detection and cancer survival rates, further support the upward trajectory of the (CEA) market in the region.

Carcinoembryonic Antigen (CEA) Market: Segmentation Analysis

The Global Carcinoembryonic Antigen (CEA) Market is Segmented on the basis of End User, Application, And Geography.

Carcinoembryonic Antigen (CEA) Market, By End User

Hospitals

Diagnostic Laboratories

Clinics

Based on End User, the market is fragmented into Hospitals, Diagnostic Laboratories, and Clinics. Hospitals lead the Carcinoembryonic Antigen ((CEA)) market as they have access to advanced diagnostic tools, competent healthcare workers, and a large volume of cancer-related treatments. Hospitals are typically the primary site of care for cancer patients, and (CEA) tests are commonly used for diagnosis and monitoring. The diagnostic laboratories industry is rapidly growing, driven by rising demand for specialized, high-precision testing and the trend of outsourcing diagnostic services. These labs have enhanced capabilities and rapid turnaround times, which strengthens their role in assisting hospitals and clinics with cancer diagnosis and management.

Carcinoembryonic Antigen (CEA) Market, By Application

Colorectal Cancer

Lung Cancer

Breast Cancer

Based on Application, the market is divided into Colorectal Cancer, Lung Cancer, and Breast Cancer. The colorectal cancer segment dominates the Carcinoembryonic Antigen ((CEA)) market since (CEA) is well established as a biomarker for monitoring and detecting recurrence in colorectal cancer patients. (CEA) testing is widely used to determine both prognosis and therapy efficacy, making it an important tool in cancer management. The lung cancer category is also fast expanding, spurred by advances in early detection and the rising global prevalence of lung cancer. With the emergence of non-invasive testing technologies, (CEA) is becoming a key marker for some forms of lung cancer, which is driving market growth.

Carcinoembryonic Antigen (CEA) Market, By Geography

Europe

North America

Asia Pacific

Rest of the world

On the basis of geographical analysis, the Global Carcinoembryonic Antigen (CEA) Market is classified into Europe, North America, Asia Pacific, and rest of the world. North America leads considering to its well-established healthcare infrastructure, strong awareness of cancer screening, and the presence of major industry participants such as Roche Diagnostics and Abbott Laboratories. The region benefits from substantial investments in cancer research and innovative diagnostic technologies. The Asia-Pacific area is experiencing the highest growth, owing to rising cancer incidence, a rapidly expanding middle class, and increased government initiatives aimed at early cancer identification. Countries such as China and India are spending considerably on healthcare infrastructure and increasing access to modern diagnostics, positioning Asia Pacific as a potential growth market for (CEA) testing.

Key Players

The "Global Carcinoembryonic Antigen (CEA) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Roche Diagnostics, Abbott Laboratories, Siemens Healthiness', Thermo Fisher Scientific, Quest Diagnostics, Beckman Coulter, and GenWay Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Carcinoembryonic Antigen (CEA) Market Recent developments
• In December 2023, Sanofi discontinued its global scientific research initiative for tusamitamab ravtansine. This decision is based on the results of a predefined intervening time analysis of the Phase 3 CARMEN-LC03 study, which compares tusamitamab ravtansine as a monotherapy to docetaxel in previously treated patients with metastatic non-squamous non-small cellular lung cancer (NSCLC).
• In May 2022, the University of Texas MD Anderson Cancer Center and Virogin Biotech announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Gastrointestinal Cancer
• 5.3 Breast Cancer
• 5.4 Lung Cancer
• 5.5 Others

6 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY GENDER

• 6.1 Overview
• 6.2 Male
• 6.3 Female

7 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY END-USERS

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Diagnostic Centres
• 7.4 Research and academic institutes
• 7.5 Family
• 7.6 Others

8 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Quest Diagnostics
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Abbott Diagnostics
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Roche Diagnostics
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GenWay Biotech Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Correlogic Systems, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Creative Diagnostics
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Omega Diagnostics Group PLC
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 RayBiotech Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Boster Biological Technology
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments

11 Appendix

• 11.1 Related Research